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Background: Our aim was to assess the associations between vitamin D (vitD) status, metabolic profile and
polymorphisms in genes involved in the transport (Group-Component: GC) and the hydroxylation (NAD synthetase 1:
NADSYN1) of 25 hydroxyvitamin D (25(OH)D) in non-diabetic individuals.
Methods: We conducted a cross-sectional study with 323 individuals recruited from the Health Center of
Guadeloupe, France. The rs2282679 T > G and rs2298849 T > C in GC and rs12785878 G > T in NADSYN1 were
genotyped.
Results: Mean age was 46(range 18–86) years. 57% of participants had vitD insufficiency, 8% had vitD deficiency,
61% were overweight and 58% had dyslipidemia. A higher frequency of overweight was noted in women carrying
rs2298849T allele v CC carriers (71% v 50%; P = 0.035). The rs2282679G allele was associated with increased risks of
vitD deficiency and vitD insufficiency (OR =3.53, P = 0.008, OR = 2.34, P = 0.02 respectively). The rs2298849 TT
genotype was associated with vitD deficiency and overweight (OR =3.4, P = 0.004 and OR = 1.76, P = 0.04
respectively) and the rs12785878 GG genotype with vitD insufficiency and dyslipidemia (OR = 1.80, P = 0.01 and
OR = 1.72, P = 0.03 respectively). Based on the number of risk alleles for rs2282679 and rs12785878 combined,
a genotype score of 3 (vs. 0–1) was associated with a 5.5 ng/mL average reduction in serum 25(OH)D levels
(P = 0.001).
Conclusions: The GC and NADSYN1 genes are associated with the vitamin D status and might contribute to
dyslipidemia and overweight independently of 25(OH)D levels.
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The storage form of vitamin D, 25-hydroxyvitamin D
(25(OH)D), measured in blood circulation is a marker of
vitamin D status. Low 25(OH)D has been associated
with increased risk of cardio-metabolic diseases, includ-
ing obesity [1], dyslipidemia [2], type 2 diabetes [3], and
cardiovascular complications [2,4]. However, genetic fac-
tors may also have effects on these diseases. In* Correspondence: lfoucan@yahoo.fr
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reproduction in any medium, provided the orparticular, single-nucleotide polymorphisms (SNPs) in
genes of the vitamin D pathway that are involved in the
transport or the hydroxylation of 25(OH)D may be asso-
ciated with the cardio-metabolic risk.
The 25(OH)D is transported in the circulation, mainly
bound to its specific vitamin D-binding protein, also
named the GC-group component (GC). As the VDR
gene [5], polymorphisms in the GC gene were previously
reported to be associated with plasma glucose levels [6],
fasting plasma insulin levels [7] and the percentage of fat
mass in Caucasian nuclear families [8].
In previous studies of 25(OH)D, variants of genes
involved in vitamin D transport (GC), hydroxylation/Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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were reported to modulate vitamin D status [9-11]. The
NADSYN1 gene encodes nicotinamide adenine dinucleo-
tide synthetase 1 (NADSYN1), which is one of the
glutamine-dependent enzymes involved in cholesterol syn-
thesis and favors the production of nicotinamide adenine
dinucleotide (NAD+), the main coenzyme required for en-
ergy production and lipid synthesis [12]. Nevertheless, stud-
ies of the association between overweight or dyslipidemia
and polymorphisms in these genes are scarce. A recent
study performed in an African-American cohort found as-
sociations between SNPs in the GC and CYP27B1 genes
and 25(OH)D with a significant relation with the degree of
African ancestry as assessed using skin color gradation [13].
In the French Caribbean island of Guadeloupe, which
has 400,000 inhabitants, about 80% of the population is
of African descent and these individuals are at risk of
vitamin D insufficiency and obesity [14,15].
Our aim was to assess the associations between vita-
min D status, overweight, dyslipidemia and four SNPs of
the GC, CYP27B1, and NADSYN1 genes in non-diabetic
individuals with African ancestry.
Methods
Population study
The participants were recruited among individuals who
had a clinical and biological examination at the referring
Health Center of Guadeloupe. Data were collected
during 2010 and 2011. For the assessment of vitamin D
status, the physician included volunteers during sessions
that were randomly planned. The determination of
African ethnic background was based on self-report.
Exclusion criteria included a history of kidney disease,
diabetes, or inflammatory disease, pregnancy, and calcium
or vitamin D replacement therapy. The study was approved
by the inter-regional ethic committee (Sud-Ouest et Outre-
Mer III, France). All patients gave their written informed
consent to participate in this study.
Data collection
Participants were interviewed by a physician using a stand-
ard questionnaire that provided information on age, sex
and use of antihypertensive and/or anti-hyperlipidemic
treatments.
Height and weight were measured with participants
standing without shoes and lightly clothed. Body mass
index (BMI) was calculated as weight/height (kg/m2).
Waist circumference (cm) was measured above the iliac
crests and below the lowest rib margin at minimal res-
piration with participants standing. The measurements
were performed by trained nurses. Systolic and diastolic
blood pressures were assessed using automated monitors
after resting for at least 5 min. The retained values were
the average of two readings (left and right arms).Laboratory measurements
Blood samples were obtained after an overnight fast.
The biochemical analyses were performed using the
same methods for the whole study sample. Glycaemia
was assessed using the glucose oxidase method.
Cholesterol, high-density lipoprotein/cholesterol, and
triglyceride levels were measured enzymatically. Plasma
concentrations of 25(OH)D were measured via a chemi-
luminescence assay (DiaSorin SA, Antony, France),
which includes 25(OH)D2 and 25(OH)D3. In this
Health Center, only single measurements were available
for all the parameters.
Genotyping
Genotyping was performed in 323 Afro-Caribbean indi-
viduals for SNPs that were reported to be associated
with vitamin D status in individuals of European de-
scents (11) or in African-Americans (14): rs2282679 (in-
tron 12) in GC, rs2298849 (intron 1) in GC, rs10877012
(5′ UTR) in CYP27B1, and rs12785878 (intronic region
of NM_018161.4) in NADSYN1. DNA was extracted
from peripheral blood samples by standard procedures.
SNPs were genotyped by KBioscience Ltd using their
own novel fluorescence-based competitive allele-specific
PCR (KASPar) assay. Details of the method used can be
found at www.kbioscience.co.uk/.
Definition of clinical factors
Obesity was defined as a BMI ≥ 30 kg/m2 and overweight
was defined as a BMI ≥ 25 kg/m2. Abdominal obesity
was defined as a waist circumference > 102 cm in men
or > 88 cm in women.
Vitamin D insufficiency was defined as a 25(OH)D
level < 30 ng/mL and vitamin D deficiency as a 25(OH)D
level < 20 ng/mL.
Dyslipidemia was defined as having one of the follow-
ing measurements: high-density lipoprotein/cholesterol
concentration < 40 mg/dL in men and < 50 mg/dL in
women, triglyceride concentration ≥ 150 mg/dL, low-
density lipoprotein/cholesterol concentration ≥ 130 mg/
L, or the presence of a lipid-lowering treatment com-
bined with a history of blood lipid abnormality [16].
Statistical analyses
The chi-squared test and ANCOVA were used to test
percentage and mean differences between groups. Serum
25(OH)D was log10 transformed to approach a normal
distribution.
We examined the associations between SNPs, vitamin D
deficiency, vitamin D insufficiency, dyslipidemia and over-
weight status. The logistic regression models were tested
including each SNP alone with adjustment for age, sex,
BMI, 25(OH)D levels, or dyslipidemia, according to the
dependent variable. Adjusted odds ratios (ORs) and 95%
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fects were presented as ORs associated with the genotypes.
We used a genotype score approach to evaluate the
combined effects of SNPs that were significantly associ-
ated with serum 25(OH)D. The genotype score is equal
to the sum of the number of risk allele (25(OH)D lower-
ing allele) in the SNPs. To evaluate the variation in 25
(OH)D levels associated with the genotype score, we ap-
plied simple and multiple linear regression analysis
methods using serum 25(OH)D level as the dependent
variable, and genotype score as the independent vari-
ables. Adjustments were performed for age, sex and
BMI. The genotype score effects were assessed by the
values of regression coefficients (beta) corresponding to
the non-standardized regression coefficients.
The IBM SPSS Statistics software version 21.0 was
used for data analyses. All tests were two-sided and a P
value < 0.05 was considered significant.Results
Characteristics of the study population
Three hundred twenty-three non-diabetic individuals
were included in the study. Among the participants, 187
(58%) were women. The mean age was 46 ± 12 years.
The characteristics of the population under study are
shown in Table 1. Among the participants, 29% were
obese, 61% were overweight, 42% had hypertension,
58% had dyslipidemia, 57% had vitamin D insufficiency
and 8% had vitamin D deficiency. In the whole study
population, the concentration of 25(OH)D ranged
from 7 to55 ng/mL and the mean serum 25(OH)D was
29 ± 8 ng/mL.
The prevalence of obesity and overweight status were
significantly higher in women than in men (38% v17%,
P < 0.001 and 68% v 52%, P = 0.004, respectively).Table 1 Characteristics of the study population
Variables N All subjects
Sex (F) (n (%)) 323 136 (58)
Age (years) 323 46 ± 12
Waist circumference (cm) 307 89 ± 13
Body mass index (Kg/m2) 323 27 ± 6
Glycaemia (mmol/L) 323 4.6 ± 1.2
25(OH)D (ng/mL) 323 29 ± 8
Overweight (n (%)) 323 198 (61)
Obesity (n (%)) 323 94 (29)
Abdominal obesity (n (%)) 307 108 (35)
Hypertension (n (%)) 323 136 (42)
Dyslipidemia (n (%)) 319 184 (58)
Vitamin D Insufficiency (n (%)) 323 183 (57)
The data are presented as mean ± SD or number (%).The genotype distributions in the study population
were within the Hardy–Weinberg equilibrium for
rs2282679 T > G (0% GG, 13% TG, 87% TT; P = 0.90),
rs2298849 T > C (15% CC, 51% TC, 34% TT; P = 0.90)
and rs12785878 G > T (5% TT, 33% GT, 62% GG; P =
0.90), but not for rs10877012 G >T (25% GT, 75% GG; P <
0.05). Consequently, the results for rs10877012 (CYP27B1)
are not shown in this report.
Distributions of 25(OH)D levels and metabolic parameters
according to genotypes
The distributions of 25(OH)D levels and metabolic pa-
rameters according to genotypes of GC and NADSYN1
genes are presented in Table 2.
For the rs2282679 SNP in the GC gene, lower values
of serum vitamin D, higher frequencies of vitamin D
insufficiency and of vitamin D deficiency were ob-
served in carriers of the TG genotype than in the
remaining individuals (P values from 0.03 to 0.01). The
association of this SNP with dyslipidemia was nearly
significant (P = 0.05).
Significant differences were noted in frequency of
vitamin D deficiency according the rs2298849 geno-
types with a higher frequency in carriers of the TT
genotype than in the non-carriers (P = 0.007). For
rs12785878, higher values for mean circulating 25(OH)
D (P = 0.03) and lower frequency of vitamin D insuffi-
ciency (P = 0.01) and dyslipidemia (P = 0.04) were
noted in carriers of the minor allele (TT/GT) com-
pared with the remainder of the cohort.
Regarding the associations of the three SNPs studied
with overweight or obesity according to sex, a higher
frequency of overweight was noted in women carrying
rs2298849T allele vs CC carriers (71% v 50%; P = 0.035)
(Table 3). In men, no relationship was found between
obesity or overweight and the three SNPs studied.Men Women P
136 __ 187 __
136 41 ± 12 187 47 ± 12 0.42
130 89 ± 11 177 90 ± 14 0.40
136 25 ± 4 187 29 ± 7 <0.001
136 4.9 ± 1.6 187 4.5 ± 0.9 0.003
136 30 ± 8 187 28 ± 7 0.006
136 71 (52) 187 127 (68) 0.004
136 23 (17) 187 71 (38) <0.001
130 13 (10) 177 95 (54) <0.001
136 56 (41) 187 80 (43) 0.77
135 69 (51) 184 115 (63) 0.04
136 68 (50) 187 115 (62) 0.04
Table 2 Distribution of 25(OH)D levels and metabolic parameters according to genotypes of GC and NADSYN1 genes
Genotypes Dominant model Recessive model
rs2282679 T > G (GC) GG TG TT P*
(N = 323) 0 43 280
25 (OH)D (ng/mL) __ 26.4 ± 8.3 29.0 ± 7.4 0.03 __ __
Vitamin D Insufficiency __ 72% 54% 0.03 __ __
Vitamin D Deficiency __ 19% 6% 0.01 __ __
Overweight __ 67% 60% 0.37 __ __
Obesity __ 35% 28% 0.37 __ __
Abdominal obesity __ 42% 34% 0.36 __ __
Dyslipidemia __ 44% 60% 0.05 __ __
rs2298849 T > C (GC) CC TC TT P* P P
(N = 323) 49 165 109
25 (OH)D (ng/mL) 28.3 ± 6.9 28.5 ± 7.7 29.0 ± 7.8 0.87 0.60 0.76
Vitamin D Insufficiency 53% 60% 53% 0.46 0.37 0.58
Vitamin D Deficiency 6% 5% 14% 0.03 0.007 0.50
Overweight 51% 61% 66% 0.20 0.21 0.11
Obesity 22% 32% 28% 0.46 0.85 0.26
Abdominal obesity 28% 39% 33% 0.32 0.37 0.27
Dyslipidemia 53% 63% 51% 0.13 0.11 0.48
rs12785878 G > T TT GT GG P* P P
(NADSYN1)(N = 318) 15 106 197
25 (OH)D (ng/mL) 27.7 ± 7.1 30.2 ± 8.3 27.8 ± 7.1 0.05 0.03 0.69
Vitamin D Insufficiency 53% 47% 62% 0.04 0.01 0.77
Vitamin D Deficiency 13% 5% 10% 0.25 0.23 0.46
Overweight 40% 62% 62% 0.22 0.60 0.08
Obesity 20% 33% 28% 0.50 0.85 0.40
Abdominal obesity 21% 39% 34% 0.37 0.37 0.17
Dyslipidemia 60% 49% 62% 0.08 0.04 0.83
The data are presented as mean (SD) or column percentage. Significant P values are presented in bold.
*P values for comparisons between genotypes.
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insufficiency, dyslipidemia and overweight.
Table 4 presents the adjusted odds ratios (OR) for risk of
vitamin D deficiency, vitamin D insufficiency, dyslipidemia
and overweight according to the GC and the NADSYN1 ge-
notypes. For rs2282679, carrying the G allele increased the
risk of vitamin D deficiency and of vitamin D insufficiencyTable 3 Frequencies of overweight according to
rs2298849 T > C genotypes in men and women
MEN WOMEN
N = 136 N = 187
Overweight TT-TC CC P TT-TC CC P
n = 103 n = 23 n = 161 n = 26
No 44 (48) 11 (48) 0.99 47 (29) 13 (50) 0.035
Yes 59 (52) 12 (52) 114 (71) 13 (50)
The data are presented number (column percentage).(adjusted OR= 3.53, P = 0.008 and adjusted OR = 2.34, P =
0.02 respectively) in comparison with the TT genotype and
surprisingly with a decreased risk of dyslipidemia.The odds
of vitamin D deficiency was significantly increased for
rs2298849 TT carriers in comparison with the rs2298849C
allele carriers (adjusted 3.40 = 1.46, P = 0.004) and that of
vitamin D insufficiency was significantly increased for
rs12785878 GG carriers (adjusted OR =1.80, P = 0.01) in
comparison to T allele carriers. The rs12785878 was also
associated with an increased risk of dyslipidemia.
Serum 25(OH)D levels in relation to genotype score
The risk alleles (25(OH)D lowering allele) were G for
rs2282679, T for rs2298849 and G for rs12785878. The
high risk alleles of rs2282679 and rs12785878 were com-
bined and the range of the genotype score was 0–3. The
genotype score was significantly related to 25(OH)D and
mean serum 25(OH)D levels (95% CI) were 30.1 (28.6 –
Table 4 Logistic regressions of vitamin D deficiency, vitamin D insufficiency, dyslipidemia and overweight for
polymorphisms in GC and NADSYN1
Vitamin D Vitamin D Dyslipidemia Overweight
deficiency Insufficiency
Adjusted P Adjusted P Adjusted P Adjusted P
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
GC rs2282679 T > G
TT 1 1 1 1
TG- GG 3.53 (1.38 - 9.80) 0.008 2.34 (1.15 - 4.90) 0.02 0.41 (0.21 - 0.84) 0.01 1.60 (0.70 – 3.36) 0.20
GC rs2298849 T > C
CC - TC 1 1 1 1
TT 3.40 (1.46 - 7.89) 0.004 0.82 (0.51 - 1.31) 0.41 0.67 (0.40 - 1.11) 0.12 1.76 (1.04 - 2.98) 0.04
NADSYN1 rs12785878 G > T
TT - GT 1 1 1 1
GG 1.72 (0.69 - 4.24) 0.54 1.80 (1.12 - 2.87) 0.01 1.72 (1.04 - 2.86) 0.03 1.02 (0.62 - 1.69) 0.93
Vitamin D deficiency and vitamin D insufficiency: adjustment for age, sex, BMI, dyslipidemia. Dyslipidemia: adjustment for age, sex, BMI, 25(OH)D levels.
Overweight: adjustment for age, sex, 25(OH)D levels, dyslipidemia. The adjusted odds ratios are provided, separately for each SNP. Significant P values are
presented in bold.
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score 2 and 24.7 (22.0 – 27.3) ng/mL for score 3, P =
0.007 (Figure 1).
Table 5 presents the results of the linear regressions
between the genotype scores across the rs2282679 and
rs12785878 SNPs and serum 25(OH)D levels. Genotype
score of 0–1 was considered as referent. In model 1 (1a,
1b, 1c) with the simple linear regression and considering
each SNP alone, significant average change in 25(OH)D
levels were noted for a rs2282679 genotype score of 2
(vs 1) (model 1a) and for a rs12785878 genotype score
of 2 (vs 0–1) (model 1c). These both models accounted
for 1% (R2 = 0.01) and 2% (R2 = 0.02), of the variation in
25(OH)D levels, respectively. In the multiple linear
regression, the average change in 25(OH)D levels
remained significant with multiple R2 of 0.06 for bothFigure 1 Mean serum 25(OH)D levels and 95% confidence
intervals according to genotype scores of two SNPs (rs2282679
T > G and rs2298849 T > C). P = 0.007.models. The rs2298849 genotype score was not signifi-
cantly associated with 25(OH)D levels. We also noted
that BMI was not related to the genotype score of the
three SNPs (rs2282679; P = 0.75, rs2298849; P = 0.65,
rs12785878; P = 0.75, data not shown).
In models 2, and in the simple regression, progressive
reductions in 25(OH)D levels were noted for score 2
and 3 (compared to 0–1): beta = −1.8 ng/mL (P = 0.04)
and beta = −5.4 ng/mL (P = 0.02) respectively. In the
multiple regression with adjustment for age, sex and
BMI, the statistically significant average change in 25
(OH)D levels for score of 3 (vs 0–1) was −5.5 ng/mL
(P = 0.001) with R2 of 0.08. The combination of both
genotype scores accounted for a 2% increase of R2. Con-
versely, this genotype score was not associated with BMI
(data not shown).
Discussion
In this study examining the relationship between vitamin
D status and SNPs of the vitamin D-binding protein
(GC) and NADSYN1 genes in non-diabetic individuals
with African ethnic background, we found significant
associations between rs2282679 (GC), rs2298849 (GC),
and rs12785878 (NADSYN1) and vitamin D status. Sig-
nificant associations were also noted with overweight for
rs2298849 and with dyslipidemia for rs12785878 and
rs2282679.
In this study population living in a sunny climate, the
prevalence of vitamin D insufficiency was 57% and that
of vitamin D deficiency was 8%. These prevalence values
were globally lower than that observed in African-
American individuals living in countries with a temper-
ate climate [14,17]. The effect of sunshine on vitamin D
levels is widely recognized.
Table 5 Linear regression: between serum 25-hydroxyvitamin D levels and genotype scores for rs2282679, rs2298849,
rs12785878
Simple linear regression Multiple linear regression**
Genotype score Beta* P R2 for the model Beta* P R2 for the model
Model 1a risk allele G for rs2282679 T > G 2 (vs 1) −2.5 0.04 0.01 −2.6 0.03 0.06
Model 1b risk allele T for rs2298849 T > C 2 (vs 0–1) 0.70 0.43 0.002
Model 1c risk allele G for rs12785878 G > T 2 (vs 0–1) −1.5 0.04 0.01 −2.1 0.02 0.06
Model 2
risk alleles G
for rs2282679 T > G and rs12785878 G > T 2 (vs 0–1) −1.8 0.04 0.03 −1.6 0.06 0.08
3 (vs 0–1) −5.4 0.02 −5.5 0.001
Model 1a, 1b include genotype scores for each SNP alone. Model 2 includes genotype scores for rs2282679 and rs12785878 combined.
Genotype score equals the sum of the number of risk alleles.*Beta: average change in serum 25(OH)D level (ng/mL) associated with the genotype. Regression: **
with adjustment for age, sex, BMI.
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as the group-specific component (GC), is the main
transporter of vitamin D [10]. The concentration of this
serum glycoprotein influences 25(OH)D levels and
modulates the rates of its bioavailability [18-20]. The GC
gene is localized on chromosome 4 (4q12–q13),
encodes a single-chain polypeptide that comprises 474
amino acid residues and belongs to the albumin
family [10,21-23].
Our results regarding vitamin D corroborate previous
reports which showed associations between vitamin D
levels and rs2282679 and rs2298849 in the GC gene in
African-Americans [13], rs2282679 in Caucasians in two
genome wide association (GWA) studies [9,11] and
rs2298849 in 496 healthy individuals [12]. In addition,
the genotype distributions of the two GC SNPs in our
African-Caribbean population were close to those ob-
served in the study conducted among AfricanAmericans
individuals [13] for rs2282679 (0.2% for the rare homo-
zygote, 15.2% for the heterozygote and the, 84.5% for
the frequent homozygote genotype) and for rs2298849
(16.4% for the rare homozygote, 46.2% for the heterozy-
gote and 37.4% for the frequent homozygote genotype).
The effects of CYP27B1 and NADSYN1 on circulating
25(OH)D were also reported in these studies [9,11] and
confirmed in a recent study in Han Chinese children
[24]. Two other SNPs in the GC gene, rs4588 and rs7041,
which have been more commonly studied, exhibited sig-
nificant associations with the levels of 25(OH)D and 1,25
(OH)2D in Hispanic- and African-Americans [25], in
Caucasian women [26], and in young Canadian adults of
East-Asian, European, and South-Asian ancestry [19].
The relationship between the NADSYN1 gene and
vitamin D status has been less studied. The NADSYN1
gene is located on chromosome 11 (11q13.4), close to
the dehydrocholesterol reductase (DHCR7) gene, which
encodes 7-dehydrocholesterol reductase, an enzyme in-
volved in the conversion of 7-dehydrocholesterol intocholesterol in human skin [27]. A recent GWA study re-
vealed that variants near genes involved in cholesterol
synthesis influence the vitamin D status [11]. The
rs12785878 GG genotype was associated with an increased
risk of vitamin D insufficiency and of dyslipidemia in our
study. This association with dyslipidemia has not already
been reported but, mutations in DHCR7 are associated with
Smith-Lemli-Opitz Syndrome in which homozygous indi-
viduals present low serum cholesterol levels [11,28] associ-
ated with other abnormalities.
Although vitamin D deficiency has been consistently
associated with obesity, some authors failed to observe
an association between BMI and some genetic variants
in the vitamin D pathway while they were associated
with 25(OH)D levels [29-32]. According to some others,
this lack of association could be explained by the fact
that linear increases in serum 25(OH)D would not have
a substantial influence on BMI [32]. Interestingly, our
results highlighted a significant association between the
rs2298849 alone and overweight (i.e. taking into account
the BMI as a categorical variable) while no relationship
was found between the rs2298849 genotype score and
BMI. We also noted a sex difference in this relationship
with women carrying the TT/TC genotypes exhibiting a
higher frequency of overweight compared with those
carrying the CC genotype, whereas no relationship was
found in men. In a study in Caucasian nuclear families,
the authors also found a female-specific association be-
tween another SNP (rs17467825) in GC and the percent-
age of fat mass [8]. This sex-specific association suggests
disparities in the sensitivity to the SNP related to female
(such as estrogen) or male (such as testosterone) hor-
mones. A possible effect of sex-hormone-binding globu-
lin should be considered. This hormone binds and
transports the sex steroid hormones (mainly testoster-
one) in the circulation [33] and its variation may con-
tribute to susceptibility to metabolic and cardiovascular
outcomes [34]. Additionally, in a recent study in Chinese
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tween BMI and SNPs in the GC gene, BMI was associated
with two other SNPs of the vitamin D pathway genes
(rs22488359 in CYP24A1 and rs10832313 in CYP2R1) [35].
This is not surprising, given that ethnic disparities in the re-
lationships between genes and diseases have been widely
reported.
The results of the linear regression of 25(OH)D
showed that the genotype score based on rs2282679 in
GC and rs12785878 in NADSYN1 alone accounted for
3% of the variation in 25(OH)D. The addition of age, sex
and BMI in the multivariate model increased the R2 by
5%. The variation in 25(OH)D associated with the gen-
etic factors is not very high [13]. Other factors such as
sun exposure, diet, ethnicity and season contributed
more significantly to this variation [36] and may also
interact with genetic effects on vitamin D status. Never-
theless, our results showing a significant average change
in 25(OH)D levels of −5.5 ng/mL for a score of 3 (vs 0–
1), is an important finding in our Afro-Caribbean popu-
lation at risk of vitamin D insufficiency.
It should be noted that the present study had some
limitations, including a small sample size although the
overall population of the island is also small (400 000 in-
habitants). Because of their low power, studies on small
samples can lead to false positive or false negative re-
sults. In addition, the concentrations of serum 25(OH)D
were examined using a single measurement for each
subject. However, our study also had considerable
strengths. First, all participants had high skin pigmenta-
tion and were living on an island which has annually a
sunny climate. This is of importance since ethnic vari-
ation in the GC gene has been described [10] and sea-
sonal variations are involved in the metabolism of
vitamin D. Second, the exclusion of patients with dia-
betes from the study minimized the impact of insulin re-
sistance/dependence [37] on the association between
SNPs, serum 25(OH)D levels, and other risk factors.
Our findings corroborated those previously reported in
European and African-American individuals regarding
genetic associations with vitamin D status and extended
the relevant studies for a specific population sample. Third,
this study is the first to analyze the effects of SNPs in the
GC and NADSYN1 genes concomitantly on three
cardio-metabolic risk factors (overweight, dyslipidemia,
and vitamin D insufficiency/deficiency).
Conclusions
Although the role of genetic factors in the metabolism
of vitamin D is recognized, much remains to be under-
stood regarding this relationship. Our results obtained
from non-diabetic Afro-Caribbean individuals confirm
the associations of the GC and NADSYN1 genes with
vitamin D status and suggest that polymorphisms inthese genes contribute to dyslipidemia and overweight
independently of 25 hydroxyvitamin D levels. As vitamin
D status is linked to several adverse outcomes [38], gen-
etic variants associated with vitamin D levels may also
play a role in the etiology of these diseases. Thus, it will
be of interest to confirm these findings in other popula-
tions and ethnic groups.
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